A new lung cancer diagnosis means tests and decisions ahead. Your oncologist will order imaging, a biopsy, staging scans, and biomarker testing. Understanding what each result means helps you ask better questions at your first appointment.
Why Biomarker Testing Comes Before Treatment
Lung cancer is not one disease. Two tumors that look identical under a microscope may have completely different genetic drivers and need very different treatments. Biomarker testing – also called molecular profiling or genomic testing – looks at genetic changes inside your tumor cells. The results tell your oncologist whether your cancer has a mutation that can be treated with a specific drug, or whether immunotherapy might work.
In non-small cell lung cancer (NSCLC), which causes most lung cancer cases, biomarker testing is standard before treatment begins. Testing rates for EGFR mutations and ALK rearrangements – the most tested biomarkers – exceed 80% in newly diagnosed NSCLC patients, according to the American Cancer Society National Lung Cancer Roundtable. Testing rates for newer biomarkers such as KRAS G12C and RET fusions are lower. Ask your oncologist which biomarkers were tested on your sample and whether you had a comprehensive next-generation sequencing (NGS) panel.
| Biomarker | Prevalence in NSCLC | Matched Therapy Type | Standard Test Method |
|---|---|---|---|
| EGFR mutation | ~8.6% in a 2024 single-center cohort; higher rates reported in Asian populations | EGFR tyrosine kinase inhibitors (TKIs) | PCR or next-generation sequencing (NGS) |
| ALK rearrangement | Less common than EGFR; varies by patient population | ALK inhibitors | FISH, immunohistochemistry, or NGS |
| KRAS mutation | ~20% in a 2024 single-center cohort; the G12C subtype has an approved targeted agent | KRAS G12C inhibitors (G12C subtype only) | NGS |
| PD-L1 expression | Scored as a percentage; level of expression guides immunotherapy eligibility | Checkpoint inhibitors (anti-PD-1 or anti-PD-L1 agents) | Immunohistochemistry (IHC) |
EGFR and KRAS figures are drawn from a 2024 single-center molecular profiling study in NSCLC. Prevalence varies across populations and testing panels.
Other Biomarkers Worth Asking About
Beyond EGFR, ALK, KRAS, and PD-L1, comprehensive NGS panels may test for ROS1 rearrangements, RET fusions, MET exon 14 skipping, NTRK fusions, HER2 mutations, and BRAF V600E mutations. A 2025 review of NSCLC management notes that FDA-approved targeted drugs now exist for each of these. If your initial biopsy sample was too small for a full panel, ask whether liquid biopsy – a blood draw that detects circulating tumor DNA – can supplement your tissue testing.
Small cell lung cancer (SCLC) grows differently from NSCLC. It grows faster and is less often driven by the mutations common in NSCLC. SCLC is usually treated with chemotherapy and, increasingly, immunotherapy. Biomarker testing is still used in SCLC but the approach differs from NSCLC.
How Lung Cancer Is Staged
Staging describes how far the cancer has spread. Your stage, combined with your biomarker results, shapes every treatment decision.
For NSCLC, oncologists use the TNM system. T describes the size and extent of the primary tumor. N describes whether cancer has reached nearby lymph nodes. M shows whether cancer has spread to distant organs. These combine into stages ranging from IA to IV.
- Stage I: The tumor is small and confined to the lung, with no lymph node spread. Surgery is usually the main treatment.
- Stage II: The tumor is larger or cancer has reached lymph nodes close to the lung. Surgery combined with chemotherapy is a common approach.
- Stage III: Cancer has spread to lymph nodes in the chest but not to distant organs. Treatment often combines chemotherapy, radiation, and sometimes immunotherapy.
- Stage IV: Cancer has spread to the other lung, fluid around the lung, or distant organs such as the brain or bones. Treatment focuses on controlling the cancer and keeping quality of life. Targeted therapies and checkpoint inhibitors are key options at this stage.
Small cell lung cancer uses a two-stage system, still used with TNM. Limited stage means disease is on one side of the chest. Extensive stage means it has spread further. Cancer Research UK offers a clear explanation of both staging systems for patients reviewing their reports.
How Biomarker Results and Stage Work Together
Your treatment plan isn’t based on stage alone. A patient with stage IV NSCLC and an EGFR mutation may receive an oral EGFR TKI as first-line therapy instead of chemotherapy. A patient at the same stage with high PD-L1 expression and no actionable mutation may receive a checkpoint inhibitor. A patient with a KRAS G12C mutation may qualify for a KRAS-specific inhibitor. Your biomarker profile and TNM stage together determine which treatments are available to you.
If your pathology report shows high PD-L1 expression and your oncologist is considering checkpoint inhibitors, the article on melatonin dosing for sleep, fatigue, and immune support during checkpoint inhibitor treatment covers support strategies for that treatment.
Integrative Care from the Day of Diagnosis
Integrative oncology provides evidence-based supportive care alongside conventional treatment. It does not replace surgery, chemotherapy, targeted drugs, or immunotherapy. Evidence is strongest for nutrition, physical activity, and certain specific supplements. Start integrative planning at diagnosis, not after problems arise.
Nutrition at Diagnosis
Malnutrition at diagnosis is common and reduces treatment tolerance. Research on nutrition screening in outpatient lung cancer patients shows that early assessment identifies those at risk for weight loss. Ask for a referral to a registered dietitian oncologist at diagnosis. If appetite loss is a concern, the article on managing appetite loss in advanced lung cancer covers practical nutrition strategies.
Green Tea Extract (EGCG) and Lung Cancer Research
Epigallocatechin gallate (EGCG), the main active compound in green tea, has been studied in lab and animal models of lung cancer. A 2023 narrative review found that EGCG stops cancer cell growth in NSCLC cell lines and that green tea drinkers have reduced lung cancer risk. The review notes that human trials are still needed to confirm whether EGCG supplements help during treatment.
A separate lab study found that EGCG may potentiate the antiproliferative activity of EGFR inhibitors in NSCLC cell lines. This is lab data, not human trials, and how EGCG works with EGFR drugs in people remains unknown. Talk to your oncologist before starting any supplement, especially if you take targeted therapy.
If your doctor approves a green tea extract, Oncostore’s Green Tea Daily 725 provides a daily EGCG supplement. Talk to your oncologist before starting any supplement. For more on the evidence for quercetin and green tea during lung cancer treatment, see Quercetin and Green Tea During Lung Cancer Immunotherapy.
Physical Activity
Exercise helps with cancer-related fatigue and supports treatment tolerance in lung cancer patients. Both aerobic exercise and strength training have been studied. A cancer-specialized physical therapist can design a plan for your fitness level and treatment schedule.
Mind-Body Practices
Mindfulness-based stress reduction, yoga, and acupuncture have been studied for managing anxiety, sleep problems, and pain in cancer patients. Evidence in lung cancer keeps growing. These practices are safe with conventional care and worth discussing with your team if you have anxiety or sleep problems at diagnosis.
Questions to Ask at Your First Appointment
- Which biomarkers were tested on my biopsy sample, and were any actionable mutations found?
- Was a comprehensive NGS panel run, or were only a limited number of genes tested?
- What is my TNM stage, and what does that mean for my treatment options?
- Is clinical trial enrollment an option given my stage and biomarker profile?
- Can I be referred to a registered dietitian oncologist and a palliative care specialist at diagnosis?
- Which supplements or herbal products are safe to continue or start during treatment?
Reviewing Integrative Formulations as Part of Your Plan
When researching supportive care, formulation quality and standardized doses matter as much as ingredient evidence. You can browse available options in the Integrative Oncology category. Talk to your oncologist or pharmacist before starting any supplement if you take prescription drugs, targeted therapy, or immunotherapy. Some supplements interact with drugs your liver processes, and timing matters. This applies too if you’re pregnant or breastfeeding.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
